Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) |
| unknown |
| Phase 2 |
| 39 |
| Guangxi Medical UniversityOTHER |
| 0 |
| Jan 9, 2020 |
| clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04025437 | Neoadjuvant Radiotherapy for HCC Involving Type I PVTT | unknown | Phase 2 / Phase 3 | 214 | Guangxi Medical UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04066543 | TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04052152 | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04035876 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | unknown | Phase 1 / Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT04014101 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma(SHR-1210) | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 66 | China Medical University, ChinaOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01047969 | Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy | unknown | Phase 2 | 99 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03966118 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma(AIO-STO-0218) | unknown | Phase 2 | 59 | P. C. Thuss-PatienceOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | unknown | Phase 2 | 35 | Pancreatic Cancer Research TeamOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer(MICADO) | unknown | Phase 2 | 51 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03837301 | Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) | unknown | Phase 2 | 88 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT02919878 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | unknown | Phase 2 | 25 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01834963 | P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. | unknown | Phase 2 | 66 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | May 18, 2018 | clinicaltrials |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | unknown | Phase 2 | 50 | Guangxi Medical UniversityOTHER | 0 | May 9, 2018 | clinicaltrials |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | unknown | Phase 2 | 40 | Guangxi Medical UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT02978547 | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma(Metformin 001) | unknown | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02311205 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)(COTSOM) | unknown | Phase 2 | 55 | Asan Medical CenterOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03337841 | Pembrolizumab as Neoadjuvant Treatment in HCC | unknown | Phase 2 | 50 | Kindai UniversityOTHER | 0 | Nov 9, 2017 | clinicaltrials |
| NCT01217034 | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib(TACTICS) | unknown | Phase 2 | 228 | Kindai UniversityOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03316326 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | unknown | Phase 2 | 35 | National Taiwan University HospitalOTHER | 0 | Oct 20, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2020source: clinicaltrials